Evidence map›Paper›PMID 36239924›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.

Jon B Toledo, Carla Abdelnour, Rimona S Weil, Daniel Ferreira, Federico Rodriguez-Porcel, Andrea Pilotto, Kathryn A Wyman-Chick, Michel J Grothe, Joseph P M Kane, Angela Taylor and 10 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  14. Article
  15. Review
  16. Article
  17. Heterogeneity of dementia with lewy bodies: Insights from clinical presentations, neuropathology, and biomarkers.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  18. Regional cortical network atrophy predicts progression to dementia in the Lewy body diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 18 institutions in 8 countries.

Jon B ToledoNantz National Alzheimer Center, Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0003-4366-9268
Carla AbdelnourFundació ACE. Barcelona Alzheimer Treatment and Research Center, Universitat Autónoma de Barcelona, Barcelona, Spain.
Rimona S WeilDementia Research Centre, Wellcome Centre for Human Neuroimaging, Movement Disorders Consortium, National Hospital for Neurology and Neurosurgery, University College London, London, UK.
Daniel FerreiraDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer's Research, Karolinska Institutet, Stockholm, Sweden.
Federico Rodriguez-PorcelDepartment of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.
Andrea PilottoDepartment of Clinical and Experimental Sciences, University of Brescia, Parkinson's Disease Rehabilitation Centre, FERB ONLUS-S, Isidoro Hospital, Trescore Balneario (BG), Italy.
Kathryn A Wyman-ChickHealthPartners Center for Memory and Aging and Struthers Parkinson's Center, Saint Paul, Minnesota, USA.
Michel J GrotheInstituto de Biomedicina de Sevilla (IBiS), Unidad de Trastornos del Movimiento, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Joseph P M KaneCentre for Public Health, Queen's University Belfast, Belfast, UK.
Angela TaylorLewy Body Dementia Association, Lilburn, Georgia, USA.
Arvid RongveDepartment of Research and Innovation, Institute of Clinical Medicine (K1), Haugesund Hospital, Norway and The University of Bergen, Bergen, Norway.
Sonja ScholzDepartment of Neurology, National Institute of Neurological Disorders and Stroke, Neurodegenerative Diseases Research Unit, Johns Hopkins University Medical Center, Baltimore, Maryland, USA.
James B LeverenzLou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
Bradley F BoeveDepartment of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Dag AarslandDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, UK.
Ian G McKeithNewcastle University Translational and Clinical Research Institute (NUTCRI, Newcastle upon Tyne, UK.
Simon LewisForeFront Parkinson's Disease Research Clinic, School of Medical Sciences, Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia.
Iracema LeroiGlobal Brain Health Institute, Trinity College Dublin, Dublin, Ireland.
John P TaylorTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
ISTAART Lewy body dementias Trial Methods Working Group
Newcastle University · GBCleveland Clinic · USDementia UK · GBFondazione Europea Ricerca Biomedica · ITHaukeland University Hospital · NOHealthPartners · USHouston Methodist · USInstituto de Biomedicina de Sevilla · ESJohns Hopkins University · USKarolinska Institutet · SEKing's College London · GBMayo Clinic · USMedical University of South Carolina · USQueen's University Belfast · GBThe University of Sydney · AUTrinity College Dublin · IEUniversitat Autònoma de Barcelona · ESWellcome Centre for Human Neuroimaging · GB

Funding

Project: Predicting PhenoconversionU19AG071754 · NIA · WASHINGTON UNIVERSITY · PI Bradley F Boeve · 2021 to 2026
$41.2M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI JAGAN AYYAPPAN PILLAI · 2021 to 2026
$23.9M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Genetic characterization of atypical parkinsonismZIANS003154 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SCHOLZ, SONJA · 2016 to 2025
$15.4M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM, MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Intramural NIH HHS ZIA NS003154NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG072959NIA NIH HHS U19 AG071754NINDS NIH HHS U01 NS100620NINDS NIH HHS U54 NS110435Wellcome Trust 205167/Z/16/Z
6 · The paper itself

Abstract

Dementia with Lewy bodies (DLB) is clinically defined by the presence of visual hallucinations, fluctuations, rapid eye movement (REM) sleep behavioral disorder, and parkinsonism. Neuropathologically, it is characterized by the presence of Lewy pathology. However, neuropathological studies have demonstrated the high prevalence of coexistent Alzheimer's disease, TAR DNA-binding protein 43 (TDP-43), and cerebrovascular pathologic cases. Due to their high prevalence and clinical impact on DLB individuals, clinical trials should account for these co-pathologies in their design and selection and the interpretation of biomarkers values and outcomes. Here we discuss the frequency of the different co-pathologies in DLB and their cross-sectional and longitudinal clinical impact. We then evaluate the utility and possible applications of disease-specific and disease-nonspecific biomarkers and how co-pathologies can impact these biomarkers. We propose a framework for integrating multi-modal biomarker fingerprints and step-wise selection and assessment of DLB individuals for clinical trials, monitoring target engagement, and interpreting outcomes in the setting of co-pathologies.

Indexed as

Lewy Body DiseaseAlzheimer DiseaseBiomarkersClinical Trials as TopicCross-Sectional StudiesDNA-Binding ProteinsHumansParkinsonian DisordersREM Sleep Behavior DisorderBiomarkersDNA-Binding ProteinsTARDBP protein, humancerebrospinal fluidclinical trialsdementiadementia with Lewy bodiesLewy body dementiaMRI neurodegenerationparkinsonismPETα-synuclein

Identifiers

PMID36239924
PMCPMC9881193
OpenAlexW4306248034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.